Literature DB >> 1838897

The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function.

M E Lesch1, M A Ferin, C D Wright, D J Schrier.   

Abstract

L-PIA, a standard A1-selective adenosine agonist, was evaluated orally in carrageenan (CRG)- and reverse passive arthus-pleurisy. White blood cell (WBC) and exudate accumulation were assessed four hours after induction of the inflammatory response. L-PIA inhibited WBC accumulation in both models with ID50's of 4.37 and 4.42 mg/kg, respectively. In contrast, exudate was inhibited by L-PIA only in the CRG pleurisy model (ID50 = 1.01 mg/kg). In mechanistic studies, L-PIA reversed the drop in circulating neutrophil count which occurred within 15 minutes after CRG injection, suggesting that L-PIA may inhibit adhesion of the cells to the endothelium. The effects of L-PIA on several parameters of rat neutrophil function were determined. Enzyme release, O2-, TXB2, and LTB4 production were monitored in response to FMLP and opsonized zymosan (SOZ) stimulation. At high concentrations, L-PIA had a mild inhibitory effect on O2- release in response to FMLP and had a moderate effect on arachidonic acid metabolite production in response to both stimuli. The other response were unaffected. These results suggest that L-PIA may prevent diapedisis or neutrophil adhesion to the endothelium, but has a minimal effect on enzyme release, O2-, LTB4 and TXB2 production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838897     DOI: 10.1007/bf01993227

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  7 in total

1.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

2.  Measurement of inflammatory reactions by a dye dilution method.

Authors:  G W Carter; P R Young; M K Martin; K W Mollison
Journal:  J Pharm Pharmacol       Date:  1982-01       Impact factor: 3.765

3.  Adenosine receptors and the regulation of adenylate cyclase.

Authors:  J Wolff; C Londos; D M Cooper
Journal:  Adv Cyclic Nucleotide Res       Date:  1981

4.  The effects of adenosine agonists on human neutrophil function.

Authors:  D J Schrier; K M Imre
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

5.  Ex vivo effects of nonsteroidal antiinflammatory drugs on arachidonic acid metabolism in neutrophils from a reverse passive Arthus reaction.

Authors:  R F Myers; J C Anthes; C J Casmer; M I Siegel
Journal:  Inflammation       Date:  1985-03       Impact factor: 4.092

6.  Adenosine promotes neutrophil chemotaxis.

Authors:  F R Rose; R Hirschhorn; G Weissmann; B N Cronstein
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

7.  Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.

Authors:  B N Cronstein; S B Kramer; G Weissmann; R Hirschhorn
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

  7 in total
  3 in total

Review 1.  Adenosine receptor agonists for promotion of dermal wound healing.

Authors:  María D Valls; Bruce N Cronstein; M Carmen Montesinos
Journal:  Biochem Pharmacol       Date:  2008-11-12       Impact factor: 5.858

2.  The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells.

Authors:  L C Esquisatto; S K Costa; E A Camargo; M T Ribela; S D Brain; G de Nucci; E Antunes
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis.

Authors:  M Carmen Montesinos; Avani Desai; Bruce N Cronstein
Journal:  Arthritis Res Ther       Date:  2006-03-06       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.